Abstract:OBJECTIVE To evaluate the dosing regimens of levofloxacin. METHODS The drug concentrations in serum and urine were assayed by HPLC method and the pharmacokinetic parameters were calculated after intravenous infusion of a single dose of 200 mg, 300 mg and 500 mg levofloxacin to healthy volunteers. The in vitro activity MIC of levofloxacin against 823 clinical isolates were determined and compared with other antimicrobial agents. Based on the above results, the PK/PD parameters C(max)/MIC and AUC/MIC were calculated and the dosing regimens of levofloxacin were proposed for infections caused by different pathogens. RESULTS The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg. The in vitro pharmacodynamic study showed that levofloxacin was highly active against Hemolytic streptococcus and Moraxella catarrhalis. It was active against Streptococcus pneumoniae (including penicillin nonsusceptible strains), Hemophilus influenzae, methicillin-sensitive Staphylococcus aureus (MSSA), Klebsiella pneumoniae and Stenotrophomonas maltophilia. Levofloxacin also had good activity against Pseudomonas aeruginosa and K.pneumoniae. However, most of isolates of enterococcal spp. were resistant to levofloxacin. Above 50% of Escherichia coli isolates were resistant to levofloxacin. Based on the results of PK/PD parameters, the adequate dosing regimens of levofloxacin should be once daily 200 mg once daily of levofloxacin was expected to be effective for the treatment of infections caused by M. catarrhalis. The regimen of 300 mg once daily could be effective for the treatment of infections caused by Hemolytic streptococcus. 500 mg once daily of levofloxacin was expected to be effective for the treatment of respiratory tract infections caused by S. pneumoniae or H. influenzae. For treatment of respiratory tract infections and urinary tract infections caused by levofloxacin-susceptible organisms including K. pneumoniae, E. coli, P. aeruginosa, and S.maltophilia, 500 mg once daily of levofloxacin was needed to obtain good clinical efficacy. But PK/PD parameters predicted that 500 mg daily of levofloxacin was not effective for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and Enterococci. CONCLUSION The proposed dosing regimens of levofloxacin based on PK/PD concepts are expected to provide good efficacy in clinical practice.

Pharmacokinetics of Levofloxacin Hydrochloride Soft Capsules, Hard Capsules and Tablets in Chinese Healthy Volunteers

Pharmacokinetics of Levofloxacin after a Single Intravenous Administration in Human

Pharmacokinetics of multiple intravenous instillation of levofloxacin in Chinese healthy subjects.

Absolute bioavailability of levofloxacin tablet in healthy Chinese male subjects

Bioequivalence of Levofloxacin Hydrochloride Tablets in Chinese Healthy Volunteers

HPLC Assay of Levofloxacin in Human Plasma and Its Relative Bioavailability

Pharmacokinetics of single 500-milligram doses of intravenous levofloxacin in middle-age healthy volunteers

Pharmacokinetics and Relative Bioavailablity of Levofloxacin Lactate Tablet in Chinese Healthy Volunteers

Pharmacokinetics of Moxifloxacin Hydrochloride Tablets in Healthy Volunteers

Pharmacokinetics And Pharmacodynamics Of Levofloxacin Injection In Healthy Chinese Volunteers And Dosing Regimen Optimization

Determination of Levofloxacin Hydrochloride in Human Plasma by HPLC and Its Pharmacokinetics

Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy C hinese volunteers and dosing regimen optimization

Determination of Levofloxacin in Healthy Human Plasma by High Performance Liquid Chromatography (HPLC) Method

Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers.

[Study of Pharmacokinetics/pharmacodynamics of Levofloxacin].

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses

Pharmacokinetics of Antofloxacin Hydrochloride, a Novel Fluoroquinolone, after Single-Dose Intravenous Administration in Healthy Chinese Male Volunteers.

Pharmacokinetics and Bioavailability Study of Fluoxetine Hydrochloride Capsules in Chinese Healthy Volunteers by LC-MS/MS Method

Pharmacokinetics of levofloxacin in patients with pneumonia

Tolerability and Pharmacokinetics of Antofloxacin Hydrochloride after Multiple Oral Dose Administration in Healthy Chinese Male Volunteers.

Pharmacokinetics of Levofloxacin Hydrochloride Tablets after a High Oral Dose